Welcome to Litha Pharma, a division of Litha Healthcare Group Limited.

Litha Healthcare Group Limited is a diversified healthcare company, listed on the Johannesburg Stock Exchange (JSE) with headquarters in Johannesburg, South Africa

The Litha Pharma division contributes significantly to the Group’s revenue and has become a key strategic area of growth for Litha. All its various business entities, (Pharmaplan, Litha Pharma, Pharma Africa, Goldex Healthcare and OTC Pharma SA) have numerous licence agreements, co-marketing and joint ventures with some well-known international healthcare companies. Access and ownership to product pipelines are an intrinsic part of its long-term strategy and there are many exciting new products in various stages of registration at the Medicines Control Council (MCC).

Recently, Litha Healthcare Group acquired Pharmaplan, a successful South African pharmaceutical company as part of a transaction with Paladin Labs, Inc. of Canada. This latest acquisition merged with Litha Pharma to form a much larger pharmaceutical division. This has provided the division with the scale it needs to position itself for growth within this sector. Through the new business development team, which is supported by our major shareholder and partner Paladin Labs, there are numerous projects under evaluation with strong and exciting growth opportunities.

Litha Pharma’s immediate business focus is to develop greater market presence in all its distribution channels, in 16 therapeutic categories as well as to expand access to prescribing healthcare professionals in both the public and private sector.

To this end, the division has gone through a re-organisation process in order to focus its efforts on prescribing practitioners, including specialists and GP’s, commercial areas including pharmacies and fast moving consumer goods (FMCG), dispensing doctors, mines and the public tender sector. The internal structure has been expanded to include more skilled key account specialists and a healthcare solutions team concentrating on CRM systems and market access. Training remains a key imperative where there will be continued investment in skills development focusing on disease and product knowledge as well as soft skills and competence enhancement.

Litha Pharma has a resource compliment of over 120 experienced sales and marketing people which have a strong relationship with the private hospital sector in all major regions of South Africa.

Key therapeutic areas of focus include:

Litha Pharma, also supplies “Name Patient Drugs”. These are medicines given special approval for patients who require them urgently and have registration in other countries but are awaiting final registration in South Africa.

Added to the above is a growing range of complementary medicines which includes brands like Formule Naturelle, Marcus Rohrer Spirulina, Smecta, Spatone and various skin care ranges.

Litha Pharma division currently comprises the following business entities:HPASA

All of which are in the process of being merged and will ultimately trade as one
Litha Pharma (Pty) Ltd Brand.